William J Sandborn

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1130-41. 2008
  2. ncbi The future of inflammatory bowel disease care
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Rev Gastroenterol Disord 9:E69-77. 2009
  3. ncbi Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 5:501-5. 2003
  4. ncbi Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
    W J Sandborn
    The Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 121:1088-94. 2001
  5. ncbi Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm
    W J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 18:263-77. 2003
  6. ncbi Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 137:1934-43.e1-3. 2009
  7. ncbi A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  8. ncbi What's new: innovative concepts in inflammatory bowel disease
    W J Sandborn
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Colorectal Dis 8:3-9. 2006
  9. ncbi Preliminary data on the use of apheresis in inflammatory bowel disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 12:S15-21. 2006
  10. ncbi Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005

Detail Information

Publications144 found, 100 shown here

  1. ncbi A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1130-41. 2008
    ..Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12/23...
  2. ncbi The future of inflammatory bowel disease care
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Rev Gastroenterol Disord 9:E69-77. 2009
    ....
  3. ncbi Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 5:501-5. 2003
    ....
  4. ncbi Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
    W J Sandborn
    The Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 121:1088-94. 2001
    ..We evaluated etanercept, a human soluble tumor necrosis factor receptor: Fc fusion protein, for the treatment of active Crohn's disease...
  5. ncbi Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm
    W J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 18:263-77. 2003
    ....
  6. ncbi Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 137:1934-43.e1-3. 2009
    ..This study was conducted to determine the efficacy and safety of mesalamine 4.8 g/day compared with 2.4 g/day for the treatment of moderately active UC...
  7. ncbi A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  8. ncbi What's new: innovative concepts in inflammatory bowel disease
    W J Sandborn
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Colorectal Dis 8:3-9. 2006
    ..Investigational pipeline molecules such as natalizumab, MLN-02, an anti-interleukin 12 antibody and sargramostim, have also shown encouraging results from early studies and are now undergoing evaluation in large clinical trials...
  9. ncbi Preliminary data on the use of apheresis in inflammatory bowel disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 12:S15-21. 2006
    ....
  10. ncbi Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  11. ncbi Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study
    William J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 4:203-11. 2006
    ..The safety of selective cyclooxygenase-2 inhibitors in patients with ulcerative colitis in remission is unknown...
  12. ncbi CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial
    W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gut 53:1485-93. 2004
    ..Targeting tumour necrosis factor alpha (TNF-alpha) has demonstrated efficacy in Crohn's disease...
  13. ncbi Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 137:1250-60; quiz 1520. 2009
    ..The efficacy of infliximab for treating patients with ulcerative colitis has been established...
  14. ncbi Biologics in inflammatory bowel disease: how much progress have we made?
    W J Sandborn
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Gut 53:1366-73. 2004
  15. ncbi Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
    W J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 17:29-42. 2003
    ....
  16. ncbi Pharmacogenomics and IBD: TPMT and thiopurines
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 10:S35-7. 2004
  17. ncbi Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers
    W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 19:1089-98. 2004
    ....
  18. ncbi Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
    W J Sandborn
    Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 17:1355-64. 2003
    ..Repifermin (keratinocyte growth factor-2) has been shown to reduce inflammation in animal models of colitis...
  19. ncbi Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial
    William J Sandborn
    Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Gastroenterology 125:380-8. 2003
    ..This study determined the effectiveness of tacrolimus for the treatment of Crohn's disease fistulas...
  20. ncbi Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
    W J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Gut 53:780-2. 2004
    ..Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma...
  21. ncbi Initial combination therapy in early Crohn's disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 371:635-6. 2008
  22. ncbi Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  23. ncbi Steroid-dependent Crohn's disease
    W J Sandborn
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Can J Gastroenterol 14:17C-22C. 2000
    ..Given the morbidity associated with prolonged corticosteroid use, medical and surgical treatment strategies to reduce steroid use should be employed routinely...
  24. ncbi Certolizumab pegol for the treatment of Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:228-38. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha...
  25. ncbi Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission
    W J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 26:987-1003. 2007
    ..Patients with Crohn's disease alternate between periods of active, symptomatic disease and periods of remission. The treatment goal for Crohn's disease is to induce and then maintain remission of symptoms...
  26. ncbi Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
    William J Sandborn
    Mayo Clinic, Rochester, MN 55905, USA
    Gut 59:1485-92. 2010
    ..Pilot studies with visilizumab, a humanised monoclonal antibody to CD3, suggest efficacy for corticosteroid-refractory ulcerative colitis (UC). A placebo-controlled trial was warranted...
  27. ncbi State-of-the-art: Immunosuppression and biologic therapy
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis 28:536-42. 2010
    ..Clinical practice should change such that combination therapy with an anti-TNF agent and azathioprine replace azathioprine in patients failing first line therapy with mesalamine and/or steroids...
  28. ncbi Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
    W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gut 56:1232-9. 2007
    ..Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial...
  29. ncbi Clinical management of pouchitis
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 127:1809-14. 2004
  30. ncbi MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials
    W J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 26:205-15. 2007
    ..Adverse event frequency was similar in all groups. Conclusion MMX mesalazine is effective and generally well tolerated for inducing clinical and endoscopic remission of active, mild-to-moderate ulcerative colitis...
  31. ncbi Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Inflamm Bowel Dis 17:141-51. 2011
    ..Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment...
  32. ncbi Biologic therapy of inflammatory bowel disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 122:1592-608. 2002
    ..Based on the early successes of infliximab, CDP571 and natalizumab, it seems certain that biologic therapy will play an important role in the future treatment of inflammatory bowel disease...
  33. ncbi Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 138:1286-96, 1296.e1-3. 2010
    ..This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients...
  34. ncbi Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
    W J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 7:192-201. 2001
    ..Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown...
  35. ncbi How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis 27:80-4. 2009
    ..These patients should be systematically evaluated for bile acid diarrhoea, steatorrhoea, bacterial overgrowth, irritable bowel syndrome and depression...
  36. ncbi Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 8:696-702.e1. 2010
    ..We sought to determine the efficacy of certolizumab pegol reinduction in patients with active Crohn's disease who respond to induction therapy with certolizumab pegol and then relapse during continuous or interrupted maintenance therapy...
  37. ncbi Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    William J Sandborn
    Division of Gastroenterology and Hepatology, 200 First Street SW, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Gastroenterol 42:338-44. 2008
    ....
  38. ncbi Clinical pharmacology of inflammatory bowel disease therapies
    W J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 2:440-5. 2000
    ....
  39. ncbi Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:621-30. 2006
    ..Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed...
  40. ncbi Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Inflamm Bowel Dis 11:707-12. 2005
    ....
  41. ncbi Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy
    Jean Frederic Colombel
    Division of Gastroenterology and Hepatology, Division of Colorectal Surgery, and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:878-83. 2004
    ..The aim was to determine whether the use of steroids, immunosuppressive agents, or infliximab prior to abdominal surgery for Crohn's disease is associated with an increased rate of early postoperative complications...
  42. ncbi Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
    Waqqas Afif
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 105:1133-9. 2010
    ..Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab concentrations are associated with decreased duration of response. We evaluated the clinical utility of measuring HACA and infliximab concentrations...
  43. ncbi Management of Crohn's disease of the ileoanal pouch with infliximab
    Jean-Frederic Colombel
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:2239-44. 2003
    ..Good pouch function requires long term treatment with infliximab in most patients...
  44. ncbi Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1941-9. 2006
    ..A history of postinflammatory pseudopolyps appears to be a predictive factor for cancer...
  45. ncbi Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastrointest Endosc 68:255-66. 2008
    ..With the introduction of new techniques to image the small bowel, there remains uncertainty about their role for diagnosing Crohn's disease...
  46. ncbi A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Gastroenterol 107:1051-63. 2012
    ..The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials...
  47. ncbi Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000
    Conor G Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 13:254-61. 2007
    ..We sought to update the incidence and prevalence of these conditions in our region through 2000...
  48. ncbi Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity
    Kelvin T Thia
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Inflamm Bowel Dis 17:1257-64. 2011
    ..This study aimed to determine the interobserver agreement (IOA) for assessment of mucosal lesions, and to determine lesions predictive of global assessment of endoscopic severity (GAES)...
  49. ncbi Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer
    Megan M Garrity-Park
    Division of Experimental Pathology and Lab Medicine, Mayo Clinic, Garrity Park, 200 First Street SW, Stabile 2 50, Rochester, MN 55905, USA
    Am J Gastroenterol 105:1610-9. 2010
    ..Surveillance in this at-risk population remains challenging. We assessed the methylation status of genes in the non-neoplastic mucosa of UC-CRC patients and controls to identify potential biomarkers of CRC...
  50. ncbi Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 107:1409-22. 2012
    ..The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD)...
  51. ncbi The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota
    Darrell S Pardi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
    Gut 56:504-8. 2007
    ..Although the epidemiology of microscopic colitis has been described in Europe, no such data exist from North America. We studied the incidence, prevalence and temporal trends of microscopic colitis in a geographically defined US population...
  52. ncbi Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis
    Chelliah R Selvasekar
    Division of Colon and Rectal Surgery, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Am Coll Surg 204:956-62; discussion 962-3. 2007
    ..Infliximab (IFX), an antitumor necrosis factor-alpha antibody, has demonstrated efficacy in medical management of CUC. The aim of this study is to determine if IFX before IPAA impacts short-term outcomes...
  53. ncbi Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:465-73. 2003
    ..Osteopenia is common in patients with ulcerative colitis (UC), but less is known about fracture risk. Previously we were unable to demonstrate increased fractures in a population-based cohort with Crohn's disease...
  54. ncbi Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease
    Jennifer Jones
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 6:1218-24. 2008
    ....
  55. ncbi Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients
    Jason M Swoger
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 16:1912-21. 2010
    ..We sought to assess the effectiveness and safety of adalimumab for the treatment of Crohn's disease (CD) in clinical practice...
  56. ncbi Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography
    David H Bruining
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 14:1701-6. 2008
    ..We also sought to examine the percentage of clinically significant new noninflammatory bowel disease (IBD) related findings in these patients...
  57. ncbi Assessment of appropriateness of indications for CT enterography in younger patients
    Luis S Guimaraes
    Department of Radiology, Mayo Clinic, Rochester, Minnestota 55905, USA
    Inflamm Bowel Dis 16:226-32. 2010
    ..We sought to determine the appropriateness of CTEs based on clinical indication in patients < or =35 years old, and the potential impact of evolution of practice to alternative magnetic resonance enterography (MRE)...
  58. ncbi Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 6:97-105. 2006
    ..Drug formulations, efficacy expectations and dose response, toxicity expectations, compliance considerations, and chemoprevention considerations are reviewed...
  59. ncbi Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
    ..CONCLUSIONS: Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day...
  60. ncbi Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease
    David H Bruining
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 9:679-683.e1. 2011
    ..However, there is little data available on how radiologic parameters of active disease change during treatment with infliximab and whether these changes correspond to symptoms, serum biomarkers, or endoscopic appearance...
  61. ncbi Risk factors for opportunistic infections in patients with inflammatory bowel disease
    Murat Toruner
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gastroenterology 134:929-36. 2008
    ..We sought to identify and quantify the clinical factors that were associated with opportunistic infections in inflammatory bowel disease patients...
  62. ncbi Perianal Crohn's disease findings other than fistulas in a population-based cohort
    Laurent Peyrin-Biroulet
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 18:43-8. 2012
    ..The cumulative incidence of and risk factors for perianal Crohn's disease (CD) for findings other than fistulas are unknown...
  63. ncbi Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease
    Kishore Malireddy
    Division of Colorectal Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Arch Surg 145:42-7. 2010
    ..To define risk factors for recurrence and to determine whether postoperative prophylaxis would influence time to recurrence after primary laparoscopic ileocolectomy for Crohn disease...
  64. ncbi Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease
    Joanna M Peloquin
    Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:2015-22. 2008
    ..However, the extent of radiation exposure in these patients is unknown...
  65. ncbi Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography
    Fargol Booya
    Department of Radiology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Radiology 241:787-95. 2006
    ..Mural hyperenhancement and increased mural thickness are the most sensitive CT findings of active Crohn disease...
  66. ncbi Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation
    Kale D Bodily
    Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Radiology 238:505-16. 2006
    ..Quantitative measures of mural attenuation are sensitive markers of small bowel inflammation...
  67. ncbi Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications
    Uma Mahadevan
    Division of Gastroenterology, University of California, San Francisco, USA
    Inflamm Bowel Dis 8:311-6. 2002
    ..CONCLUSION: Early complications after restorative proctocolectomy for ulcerative colitis are associated with high dose steroids and severe disease but not use of azathioprine/6-mercaptopurine...
  68. ncbi Inflammatory bowel disease in the setting of autoimmune pancreatitis
    Karthik Ravi
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Inflamm Bowel Dis 15:1326-30. 2009
    ..Despite scattered case reports, the prevalence of inflammatory bowel disease (IBD) in patients with autoimmune pancreatitis (AIP) is unknown. We sought to better characterize the putative association between the conditions...
  69. ncbi Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
    P W Lowry
    Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Gut 49:656-64. 2001
    ....
  70. ncbi Transcending conventional therapies: the role of biologic and other novel therapies
    W J Sandborn
    Mayo Medical School, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 7:S9-16. 2001
    ..The development of these new therapies is an exciting advance that promises to improve the management of Crohn's disease and expand current knowledge of underlying pathophysiologic mechanisms...
  71. ncbi Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
    Uma Mahadevan
    Division of Gastroenterology and Hepatology, University of California, San Francisco, 55905, USA
    Am J Gastroenterol 97:910-4. 2002
    ..CONCLUSIONS: Our preliminary results suggest that cyclooxygenase-2 inhibitors may be safe and beneficial in most patients with IBD. A placebo-controlled trial to confirm these preliminary observations is needed...
  72. ncbi Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    Gary R Lichtenstein
    Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 5:95-102. 2007
    ..We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis...
  73. ncbi New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 5:10-8. 2005
    ..This article reviews new concepts in the treatment of Crohn's disease and ulcerative colitis with a variety of anti-TNF biologic therapies: infliximab, adalimumab, CDP870, CDP571, etanercept, and onercept...
  74. ncbi Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:1737-45. 2008
    ..We sought to describe the types of colectomy, follow-up surgical/diagnostic procedures, and complications occurring within 180 days of colectomy in a population of privately insured individuals with ulcerative colitis (UC)...
  75. ncbi Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA
    Inflamm Bowel Dis 10:657-60. 2004
    ..Mechanisms by which azathioprine and infliximab may impair the natural defense mechanisms against Pneumocystis are discussed...
  76. ncbi How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 4:S25-33. 2004
    ..Some, or all, of these therapies will likely represent important treatments for Crohn's disease in the future...
  77. ncbi Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study
    Kelvin T Thia
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 15:17-24. 2009
    ..Although metronidazole and ciprofloxacin are used to treat perianal Crohn's disease (CD), no placebo-controlled trials have been performed...
  78. ncbi Crohn's disease of the esophagus: clinical features and outcomes
    G A Decker
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 7:113-9. 2001
    ..Immune modifier therapy should be considered for steroid-dependent and steroid-resistant cases...
  79. ncbi MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations
    G R Lichtenstein
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Aliment Pharmacol Ther 27:1094-102. 2008
    ..Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis...
  80. ncbi Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials
    William J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1780-7. 2005
    ..CONCLUSION: Budesonide 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse at 3 and 6 months but not 12 months in patients with CD in medically induced remission...
  81. ncbi Advances in the treatment of Crohn's disease
    Laurence J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 126:1574-81. 2004
    ....
  82. ncbi The natural history of adult Crohn's disease in population-based cohorts
    Laurent Peyrin-Biroulet
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 105:289-97. 2010
    ..This comprehensive review summarizes our current knowledge of the natural history of Crohn's disease in adults as reported in population-based studies that include long-term follow-up results...
  83. ncbi Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine
    Carlton W Thomas
    Division of Gastroenterology and Hepatology, Division of Clinical Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, U.S.A
    Inflamm Bowel Dis 9:237-45. 2003
    ..Measurement of mean corpuscular volume is a simple and inexpensive alternative to measurement of 6-thioguanine nucleotide concentrations in patients treated with azathioprine or 6-mercaptopurine...
  84. ncbi Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:2372-82. 2003
    ....
  85. ncbi Management of Crohn's disease in adults
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 104:465-83; quiz 464, 484. 2009
    ..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time...
  86. ncbi Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease
    Carlton W Thomas
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Inflamm Bowel Dis 10:28-31. 2004
    ..CONCLUSION: This case report describes the onset of a demyelinating process after the institution of infliximab therapy in a patient with Crohn's disease...
  87. ncbi Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 15:566-75. 2009
    ..We describe colectomy subtypes, follow-up surgical and diagnostic procedures, complications, and direct medical charges occurring within 180 days of colectomy among privately insured patients with ulcerative colitis (UC)...
  88. ncbi Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 123:468-75. 2002
    ..Osteoporosis is common in patients with Crohn's disease, but less is known about their risk of actual fractures...
  89. ncbi Epidemiology of inflammatory bowel disease
    Edward V Loftus
    Department of Medicine, Mayo Medical School, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 31:1-20. 2002
    ..Regardless of the exact prevalence, the burden of disease in North America and Europe is significant. Studying the patterns of geographic variation and age and gender distribution may yield important clues to the cause of IBD...
  90. ncbi Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine
    Gerald A Dayharsh
    Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 122:72-7. 2002
    ..CONCLUSIONS: Treatment of inflammatory bowel disease with azathioprine or 6-mercaptopurine appears to be associated with a small increased risk of Epstein-Barr virus-positive lymphoma...
  91. ncbi Internet use by patients in an inflammatory bowel disease specialty clinic
    Robert R Cima
    Division of Colon and Rectal Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Inflamm Bowel Dis 13:1266-70. 2007
    ..Our aim was to evaluate internet use to gather general health- and disease-specific information in patients presenting to an IBD clinic...
  92. ncbi MHC Class II alleles in ulcerative colitis-associated colorectal cancer
    M M Garrity-Park
    Division of Experimental Pathology and Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gut 58:1226-33. 2009
    ..Furthermore, since methylation of the Class II transactivator (CIITA) gene may silence HLA expression in tumours, we correlated HLA allele frequencies with CIITA gene methylation and HLA-DR expression...
  93. ncbi Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
    G R Lichtenstein
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Aliment Pharmacol Ther 30:210-26. 2009
    ..Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated...
  94. ncbi The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 16:51-60. 2002
    ..To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America...
  95. ncbi Systematic review: the management of pouchitis
    D S Pardi
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Aliment Pharmacol Ther 23:1087-96. 2006
    ..The most important test for diagnosis is pouch endoscopy with biopsy. Antibiotics remain the mainstay of treatment, and other options are discussed for those patients who are refractory to antibiotic therapy...
  96. ncbi The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study
    W A Faubion
    Division of Gastroenterology and Hepatology, Section of Biostatistics, Mayo Clinic and Foundation, 200 1st Street, Rochester, MN 55905, USA
    Gastroenterology 121:255-60. 2001
    ..CONCLUSIONS: Most patients with Crohn's disease and ulcerative colitis initially respond to corticosteroids. At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation...
  97. ncbi Cyclosporin for refractory ulcerative colitis
    C G Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gut 52:172-3. 2003
  98. ncbi Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
    L J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 274:26448-53. 1999
    ..These findings highlight the importance of inducible phosphorylation of RelA in the control of NF-kappaB activity...
  99. ncbi Total laparoscopic proctocolectomy with Brooke ileostomy: a novel incisionless surgical treatment for patients with ulcerative colitis
    D W Larson
    Division of Colon and Rectal Surgery Mayo Clinic Rochester, Mayo Clinic, Gonda 9 S, 200 Fisrt Street SW, Rochester, MN 55905, USA
    Surg Endosc 19:1284-7. 2005
    ..This report describes the clinical benefits and safety of a novel (incisionless) laparoscopic operation for chronic ulcerative colitis...
  100. ncbi Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?
    D S Pardi
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Gut 54:321-2. 2005
  101. ncbi PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Gut 54:91-6. 2005
    ..Inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD) may have a high prevalence of rectal sparing, backwash ileitis, and colorectal neoplasia...